Table 1.
Characteristics of the included randomized control trials.
| Source | Trial Design | Country (Study Name) | Population (DM) | Case (Mean Age) | Males | Aspirin Dosage | Mean Follow up (Completion Rate) |
|---|---|---|---|---|---|---|---|
| MRC 1998 [27] | PC, RCT | UK (TPT) | Patients at high risk of IHD (type 1 and 2) | 68 (57.3 years *) | 100.0 | 75 mg/daily | 6.7 years/98.9 |
| Hansson et al. 1998 [28] | DB, RCT | Globally (HOT) | Participants with hypertension (type 1 and 2) | 1501 (61.5 years) | NR | 75 mg/daily | 3.8 years/97.4 |
| Sacco et al. 2003 [29] | MC, OP, RCT, 2 × 2 factorial design | Italy (PPP) | Participants > 50 years with > one cardiovascular risk factor (type 2) | 1031 (64.2 years) | 48.2 | 100 mg/daily | 3.6 years/99.3 |
| Ridker et al. 2005 [30] | MC, DB, RCT, 2 × 2 factorial design | USA (WHS) | Healthy women (NA) | 1027 (54.6 years *) | 0 | 100 mg/every other day | 10.1 years/99.4 |
| Belch et al. 2008 [31] | DB, RCT, 2 × 2 factorial design | UK (POPADAD) | Patients aged ≥ 40 years plus ABP ≤ 0.99 (type 1 and 2) | 1276 (60 years) | 44.1 | 100 mg/daily | 6.7 years/99.5 |
| Ikeda et al. 2014 [32] | OP, RCT | Japan (JPPP) | Elderly with multiple atherosclerotic risk factors (NR) | 4903 (70.6 years *) | NR | 100 mg/daily | 5.0 years/98.7 |
| Saito et al. 2017 [10] | MC, OP, RCT | Japan (JPAD2) | Patients with Type 2 Diabetes (type 2) | 2160 (64.4 years) | 55.5 | 81 or 100 mg/daily | 10.3 years/63.8 |
| ASCEND group 2018 [8] | DB, RCT | UK (ASCEND) | Patients with diabetes (type 1 and 2) | 15,800 (63.3 years) | 62.6 | 100 mg/daily | 7.4 years/99.1 |
| McNeil et al. 2018 [9] | DB, RCT | USA/Australia (ASPREE) | Health older (NR) | 2057 (74 years *) | 44 | 100 mg/daily | 4.7 years/97.2 |
DM: diabetes mellitus; MC: multi-center; DB: double blind; OP: open label; RCT: randomized control trial; NR: Not reported; ABP: Ankle brachial pressure; TPT: thrombosis prevention trial; HOT: hypertension optimal treatment; PPP: primary prevention project; WHS: women’s health study; WHS: women’s health study; POPADAD: prevention of progression of arterial disease and diabetes; JPAD2: Japanese primary prevention of atherosclerosis with aspirin for diabetes 2, followed up study from JPAD [33]; JPPP: Japanese primary prevention project; ASCEND: a study of cardiovascular events in diabetes; ASPREE: Aspirin in reducing events in the elderly. *: data extracted from specific diabetes patients.